Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination of p38 MAPK inhibitor with PD-L1 antibody effectively prolongs survivals of temozolomide-resistant glioma-bearing mice via reduction of infiltrating glioma-associated macrophages and PD-L1 expression on resident glioma-associated microglia

Published:2021-07 Issue:3 Volume:38 Page:189-200
ISSN:1433-7398
Container-title:Brain Tumor Pathology
language:en
Short-container-title:Brain Tumor Pathol

Author:

Dang Weiqi,Xiao Jingfang,Ma Qinghua,Miao Jingya,Cao Mianfu,Chen Lu,Shi Yu,Yao Xiaohong,Yu Shichang,Liu Xindong,Cui Youhong,Zhang Xia,Bian Xiuwu

Funder

National Natural Science Foundation of China

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Clinical Neurology,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10014-021-00404-3.pdf

Reference41 articles.

1. Stupp R, Hegi ME, Mason WP et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466

2. Stupp R, Hegi ME, Gilbert MR et al (2007) Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol 25(26):4127–4136

3. Miyazaki T, Ishikawa E, Matsuda M et al (2020) Infiltration of CD163-positive macrophages in glioma tissues after treatment with anti-PD-L1 antibody and role of PI3Kgamma inhibitor as a combination therapy with anti-PD-L1 antibody in in vivo model using temozolomide-resistant murine glioma-initiating cells. Brain Tumor Pathol 37(2):41–49

4. Cohen EEW, Soulieres D, Le Tourneau C et al (2019) Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet 393(10167):156–167

5. Garon EB, Rizvi NA, Hui R et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018–2028

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TIM-3/CD68 double-high expression in Glioma: Prognostic characteristics and potential therapeutic approaches;International Immunopharmacology;2024-09

2. PD-1/PD-L1 axis: implications in immune regulation, cancer progression, and translational applications;Journal of Molecular Medicine;2024-06-27

3. Microglia and macrophages in glioblastoma: landscapes and treatment directions;Molecular Oncology;2024-05-07

4. PD-1/PD-L1 axis is involved in the interaction between microglial polarization and glioma;International Immunopharmacology;2024-05

5. Glioma hexokinase 3 positively correlates with malignancy and macrophage infiltration;Metabolic Brain Disease;2024-04-30

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3